Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study

Calliditas Therapeutics AB (publ) (”Calliditas”) today announced supportive post-hoc results from its clinical Phase 2b study NEFIGAN of the company’s lead candidate Nefecon, presented by Prof. Bengt Fellström at the International IgA Nephropathy Network meeting (IIgANN) in Buenos Aires, Argentina, on September 28, 2018.
The oral presentation of the abstract – with the title Treatment of IgA nephropathy with Nefecon, a targeted‑release formulation of budesonide – extended posthoc results from the Nefigan trial – highlighted among other things, that Nefecon has a potential to become an effective IgAN specific treatment, targeting intestinal mucosal immunity, upstream of disease manifestation.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH